English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

espanolObjetivo: Describir la incidencia de complicaciones en pacientes que iniciaron tratamiento con Acenocumarol, asi como analizar los factores asociados, la etiologia de las complicaciones y mortalidad de dichos pacientes. Metodo: Estudio observacional, descriptivo, retrospectivo. Se selecciono una muestra aleatoria de pacientes de entre aquellos que iniciaron Acenocumarol en 2015. Resultados: 124 pacientes fueron incluidos. El 56,5% eran hombres. No se encontraron diferencias estadisticamente significativas entre la aparicion de complicaciones y las comorbilidades estudiadas. Tampoco se encontro relacion entre el desajuste de los niveles de INR y la intercurrencia de una complicacion. Los pacientes con desajustes de INR presentaron un mayor numero de ingresos hospitalarios. Conclusiones: La prevalencia de complicaciones hemorragicas en el primer ano fue del 12%, siendo mayor en los primeros meses tras el comienzo con Acenocumarol EnglishObjective: To describe the incidence of bleeding complications during treatment with Acenocumarol, as well as associated factors, ethiology of this complications and patient´s mortality. Method: Retrospective, observational and descriptive review. A randomly sample of patient was collected from those who started Acenocumarol in 2015. Results: 124 patients were included. 56,5% were men. No statistically significant differences were found between the occurrence of complications and comorbidities. There was also no relation between the mismatch of the INR levels and the intercourse of a complication. There was also no relation between the mismatch of the levels of INR and the presence of complications. Conclusions: Bleeding complications prevalence during first year were 12%, being greater in the first months after starting with Acenocumarol

Complicaciones hemorrágicas en el primer año de tratamiento con Acenocumarol